Literature DB >> 6540127

Specific and nonspecific mechanisms of action of immunoglobulin G in therapy of idiopathic thrombocytopenic purpura (ITP).

T W Jungi, P Imbach, S Barandun.   

Abstract

The efficacy of IgG infusion therapy in ITP is now established even in cases resistant to other forms of therapy. However, the mechanism of action is still speculative. We assume that a correction of the elevated thrombocyte clearance is brought about at several levels. First, antibodies specific for an inciting antigen (and for which the patient is deficient) may remove free antigen and/or immune complexes which adhere to platelet surfaces, thereby rendering platelets less susceptible to clearance. Second, IgG may act nonspecifically by protecting the platelet surface from becoming covered with immune complexes. Third, monomeric IgG may display a nonspecific inhibitory effect at the level of the interaction of immunologically altered platelets with Fc receptors of mononuclear phagocytes. For the latter effect, good in vivo evidence exists. However, it must be born in mind that interaction of antibodies with Fc receptors is but one mechanisms for triggering adherence and endocytosis. A variety of other receptors and binding sites exists which may interact with immunologically altered thrombocytes. These may either trigger phagocytes on their own or facilitate the interaction of antibodies and Fc receptors. How IgG infusion influences such interactions remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540127     DOI: 10.1007/bf00319961

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  30 in total

Review 1.  NIH conference. Pathophysiology of immune hemolytic anemia.

Authors: 
Journal:  Ann Intern Med       Date:  1977-08       Impact factor: 25.391

2.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

3.  Augmentation of phagocytosis by a specific fibronectin fragment that links particulate activators to the fibronectin adherence receptor of human monocytes.

Authors:  J K Czop; K F Austen
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

4.  Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura.

Authors:  J Winiarski; G Holm
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

5.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

6.  Simultaneous enzymo-immunologic assays of platelet associated IgG, IgM and C3. A useful tool in assessment of immune thrombocytopenias.

Authors:  G Follea; B Mandrand; M Dechavanne
Journal:  Thromb Res       Date:  1982-05-15       Impact factor: 3.944

7.  Development of functional complement receptors during in vitro maturation of human monocytes into macrophages.

Authors:  S L Newman; R A Musson; P M Henson
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

8.  High-dose intravenous IgG in adults with autoimmune thrombocytopenia.

Authors:  A C Newland; J G Treleaven; R M Minchinton; A H Waters
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

9.  Complement-fixing platelet autoantibodies in autoimmune thrombocytopenia.

Authors:  W Kayser; C Meuller-Eckhardt; U Budde; R E Schmidt
Journal:  Am J Hematol       Date:  1981-09       Impact factor: 10.047

10.  Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation.

Authors:  C Bianco; F M Griffin; S C Silverstein
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  2 in total

1.  Successful treatment with high-dose intravenous immunoglobulin in a patient with spontaneous inhibitor to factor VIII.

Authors:  E Hiller; E Holler; R G Geursen; H Riess
Journal:  Blut       Date:  1986-02

2.  Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: a prospective multicenter study.

Authors:  B Imholz; P Imbach; C Baumgartner; W Berchtold; G Gaedicke; E Gugler; A Hirt; W Hitzig; C Mueller-Eckhardt; H P Wagner
Journal:  Blut       Date:  1988-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.